Phage Therapy (Biocontrol*): Light and Shade Visit new site : Sellanophagetherapy.blogspot.com: Acinetobacter baumannii (MDR), first part

"In silico"

From Wikipedia
If the target host* of a phage therapy treatment is not an animal the term "biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

In silico
From:"Genomics,Proteomics and Clinical Bacteriology",N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.

Colonies are 1 to 2 mm, nonpigmented, domed, and mucoid, with smooth to pitted surfaces.

Acinetobacter baumannii: An Emerging Multidrug-resistant Threat

Wikipedia:Acinetobacter baumannii

Acinetobacter spp.

Acinetobacter

Example of trend in Phage Therapy research

OBJECTIVE: Develop an antibiotic solution or substance consisting of least three different lytic bacteriophages that kill Acinetobacter baumannii for eventual use in human wound infections.

Development of Bacteriophage Therapy for Treatment of A. baumannii Infected Wounds

E	Enterococcus faecium	Third most common cause of HCA BSI. Increasing resistance to vancomycin.
S	Staphylococcus aureus (MRSA)	Emerging resistance to current drugs and significant drug toxicities. Lack of oral agents for step-down therapy
K	Klebsiella Escherichia coli K pneumoniae	ESBL-producing organisms increasing in frequency and severity; associated with increasing mortality. K pneumoniae carbapenemases causing severe infections in LTCF. Few active agents; nothing in development
A	Acinetobacter baumannii	Increasing worldwide, recent surge reported in hospitals. Very high mortality. Carbapenem-resistant.
P	Pseudomonas aeruginosa	Increasing P. aeruginosa infections in US and worldwide. Resistant to carbapenems, quinolones, aminoglycosides
E	Enterobacter species	MDR HCA infections increasing; resistance via ESBLs, carbapenemases, and cephalosporinases

E	Enterococcus faecium
S	Staphylococcus aureus (MRSA)	+
K	Klebsiella Escherichia coli K pneumoniae
A	Acinetobacter baumannii	+
P	Pseudomonas aeruginosa	++
E	Enterobacter species

Phage Therapy (Biocontrol*): Light and Shade Visit new site : Sellanophagetherapy.blogspot.com

messaggio

New site clik on the image

"In silico"

Phage Therapy is influenced by:

Sunday, 17 May 2009

Acinetobacter baumannii (MDR), first part